Targeting phosphoinositide 3-kinase-Moving towards therapy

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 1, 2008, Pages 159-185

  Marone, Romina ^a   Cmiljanovic, Vladimir ^a   Giese, Bernd ^a   Wymann, Matthias P ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Allergy; Cancer; Drug development; Inflammation; Pharmacology; PI3K

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; AS 604850; BAY 247; D 030; DNA DEPENDENT PROTEIN KINASE; GENE PRODUCT; GROWTH FACTOR RECEPTOR; KU 55399; LIPHAGAL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK 239; PIK 294; PIK 39; PIK 90; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TEP1; PX 866; TARGET OF RAPAMYCIN KINASE; TGX 286; TUBERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765;

ALLERGY; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; ATM GENE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC DISEASE; CLINICAL TRIAL; CYTOSKELETON; DEGRANULATION; DIABETES MELLITUS; DISEASE COURSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME STRUCTURE; GENE; GENE LOCUS; GENE MUTATION; GENE TARGETING; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LUPUS ERYTHEMATOSUS; MAST CELL; MAST CELL DEGRANULATION; METABOLIC REGULATION; MITOGENESIS; NEOPLASM; NONHUMAN; OBESITY; PATENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; CELL CYCLE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMMUNE SYSTEM DISEASES; METABOLIC DISEASES; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MURINAE; MUS;

EID: 38149120449     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.10.003     Document Type: Review

References (266)

1. Whitman M., Kaplan D.R., Schaffhausen B., Cantley L., and Roberts T.M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315 (1985) 239-242
2. Sugimoto Y., Whitman M., Cantley L.C., and Erikson R.L. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 2117-2121
3. Macara I.G., Marinetti G.V., and Balduzzi P.C. Transforming protein of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase activity: possible role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 2728-2732
4. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev., Cancer 6 (2006) 184-192
5. Wymann M.P., and Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opin. Cell Biol. 17 (2005) 141-149
6. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev., Cancer 2 (2002) 489-501
7. MacDougall L.K., Domin J., and Waterfield M.D. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr. Biol. 5 (1995) 1404-1415
8. Leevers S.J., Weinkove D., MacDougall L.K., Hafen E., and Waterfield M.D. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15 (1996) 6584-6594
9. Morris J.Z., Tissenbaum H.A., and Ruvkun G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382 (1996) 536-539
10. Roggo L., Bernard V., Kovacs A.L., Rose A.M., Savoy F., Zetka M., Wymann M.P., and Muller F. Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane. EMBO J. 21 (2002) 1673-1683
11. Chen L., Iijima M., Tang M., Landree M.A., Huang Y.E., Xiong Y., Iglesias P.A., and Devreotes P.N. PLA2 and PI3K/PTEN pathways act in parallel to mediate chemotaxis. Dev. Cell 12 (2007) 603-614
12. Schu P.V., Takegawa K., Fry M.J., Stack J.H., Waterfield M.D., and Emr S.D. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260 (1993) 88-91
13. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev., Genet. 7 (2006) 606-619
14. Wymann M.P., and Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1436 (1998) 127-150
15. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70 (2001) 535-602
16. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
17. Stephens L.R., Jackson T.R., and Hawkins P.T. Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system?. Biochim. Biophys. Acta 1179 (1993) 27-75
18. Wymann M.P., Zvelebil M., and Laffargue M. Phosphoinositide 3-kinase signaling-Which way to target?. Trends Pharmacol. Sci. 24 (2003) 366-376
19. Falasca M., and Maffucci T. Role of class II phosphoinositide 3-kinase in cell signaling. Biochem. Soc. Trans. 35 (2007) 211-214
20. Domin J., Gaidarov I., Smith M.E., Keen J.H., and Waterfield M.D. The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J. Biol. Chem. 275 (2000) 11943-11950
21. Gaidarov I., Smith M.E., Domin J., and Keen J.H. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7 (2001) 443-449
22. Maffucci T., Cooke F.T., Foster F.M., Traer C.J., Fry M.J., and Falasca M. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169 (2005) 789-799
23. Herman P.K., Stack J.H., and Emr S.D. An essential role for a protein and lipid kinase complex in secretory protein sorting. Trends Cell Biol. 2 (1992) 363-368
24. Murray J.T., Panaretou C., Stenmark H., Miaczynska M., and Backer J.M. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. Traffic 3 (2002) 416-427
25. Christoforidis S., Miaczynska M., Ashman K., Wilm M., Zhao L., Yip S.C., Waterfield M.D., Backer J.M., and Zerial M. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol. 1 (1999) 249-252
26. Kihara A., Noda T., Ishihara N., and Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 152 (2001) 519-530
27. Kihara A., Kabeya Y., Ohsumi Y., and Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2 (2001) 330-335
28. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.L., Mizushima N., Ohsumi Y., Cattoretti G., and Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 112 (2003) 1809-1820
29. Yue Z., Jin S., Yang C., Levine A.J., and Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15077-15082
30. Dann S.G., and Thomas G. The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 580 (2006) 2821-2829
31. Gulati P., and Thomas G. Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem. Soc. Trans. 35 (2007) 236-238
32. Nobukuni T., Kozma S.C., and Thomas G. hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. Curr. Opin. Cell Biol. 19 (2007) 135-141
33. Balla A., and Balla T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol. 16 (2006) 351-361
34. Balla A., Tuymetova G., Barshishat M., Geiszt M., and Balla T. Characterization of type II phosphatidylinositol 4-kinase isoforms reveals association of the enzymes with endosomal vesicular compartments. J. Biol. Chem. 277 (2002) 20041-20050
35. Heilmeyer L.M.J., Vereb G.J., Vereb G., Kakuk A., and Szivak I. Mammalian phosphatidylinositol 4-kinases. IUBMB Life 55 (2003) 59-65
36. Wong K., Meyers D., and Cantley L.C. Subcellular locations of phosphatidylinositol 4-kinase isoforms. J. Biol. Chem. 272 (1997) 13236-13241
37. Balla A., Vereb G., Gulkan H., Gehrmann T., Gergely P., Heilmeyer L.M.J., and Antal M. Immunohistochemical localisation of two phosphatidylinositol 4-kinase isoforms, PI4K230 and PI4K92, in the central nervous system of rats. Exp. Brain Res. 134 (2000) 279-288
38. Zolyomi A., Zhao X., Downing G.J., and Balla T. Localization of two distinct type III phosphatidylinositol 4-kinase enzyme mRNAs in the rat. Am. J. Physiol., Cell Physiol. 278 (2000) C914-C920
39. Kim M., Jiang L.H., Wilson H.L., North R.A., and Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 20 (2001) 6347-6358
40. de Graaf P., Klapisz E.E., Schulz T.K., Cremers A.F., Verkleij A.J., and van Bergen en Henegouwen P.M. Nuclear localization of phosphatidylinositol 4-kinase beta. J. Cell Sci. 115 (2002) 1769-1775
41. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev., Cancer 3 (2003) 155-168
42. Abraham R.T. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst.) 3 (2004) 883-887
43. Durocher D., and Jackson S.P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?. Curr. Opin. Cell Biol. 13 (2001) 225-231
44. Hiom K. DNA repair: how to PIKK a partner. Curr. Biol. 15 (2005) R473-R475
45. Yamashita A., Kashima I., and Ohno S. The role of SMG-1 in nonsense-mediated mRNA decay. Biochim. Biophys. Acta 1754 (2005) 305-315
46. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
47. Hawkins P.T., Anderson K.E., Davidson K., and Stephens L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34 (2006) 647-662
48. Polak P., and Hall M.N. mTORC2 caught in a SINful Akt. Dev. Cell 11 (2006) 433-434
49. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
50. Feng J., Park J., Cron P., Hess D., and Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279 (2004) 41189-41196
51. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-A major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
52. Brazil D.P., Park J., and Hemmings B.A. PKB binding proteins. Getting in on the Akt. Cell 111 (2002) 293-303
53. Kisseleva M.V., Wilson M.P., and Majerus P.W. The isolation and characterization of a cDNA encoding phospholipid-specific inositol polyphosphate 5-phosphatase. J. Biol. Chem. 275 (2000) 20110-20116
54. Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., and Lucas D.M. Structure, function, and biology of SHIP proteins. Genes Dev. 14 (2000) 505-520
55. Kalesnikoff J., Sly L.M., Hughes M.R., Buchse T., Rauh M.J., Cao L.P., Lam V., Mui A., Huber M., and Krystal G. The role of SHIP in cytokine-induced signaling. Rev. Physiol., Biochem. Pharmacol. 149 (2003) 87-103
56. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
57. Burgering B.M., and Kops G.J. Cell cycle and death control: long live forkheads. Trends Biochem. Sci. 27 (2002) 352-360
58. Alvarez B., Martinez-A C., Burgering B.M., and Carrera A.C. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413 (2001) 744-747
59. Burgering B.M., and Medema R.H. Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol. 73 (2003) 689-701
60. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
61. Foijer F., and te Riele H. Check, double check: the G2 barrier to cancer. Cell Cycle 5 (2006) 831-836
62. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
63. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997) 687-689
64. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
65. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev., Immunol. 2 (2002) 725-734
66. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
67. Pan D., Dong J., Zhang Y., and Gao X. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 14 (2004) 78-85
68. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
69. Martin D.E., and Hall M.N. The expanding TOR signaling network. Curr. Opin. Cell Biol. 17 (2005) 158-166
70. Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., Marengo S., Russo G., Azzolino O., Rybalkin S.D., Silengo L., Altruda F., Wetzker R., Wymann M.P., Lembo G., and Hirsch E. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (2004) 375-387
71. Vecchione C., Patrucco E., Marino G., Barberis L., Poulet R., Aretini A., Maffei A., Gentile M.T., Storto M., Azzolino O., Brancaccio M., Colussi G.L., Bettarini U., Altruda F., Silengo L., Tarone G., Wymann M.P., Hirsch E., and Lembo G. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J. Exp. Med. 201 (2005) 1217-1228
72. Alloatti G., Marcantoni A., Levi R., Gallo M.P., Del Sorbo L., Patrucco E., Barberis L., Malan D., Azzolino O., Wymann M., Hirsch E., and Montrucchio G. Phosphoinositide 3-kinase gamma controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Lett. 579 (2005) 133-140
73. Okkenhaug K., and Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev., Immunol. 3 (2003) 317-330
74. Bi L., Okabe I., Bernard D.J., Wynshaw-Boris A., and Nussbaum R.L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274 (1999) 10963-10968
75. Bi L., Okabe I., Bernard D.J., and Nussbaum R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome 13 (2002) 169-172
76. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S.E., Salpekar A., Waterfield M.D., Smith A.J., and Vanhaesebroeck B. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
77. Clayton E., Bardi G., Bell S.E., Chantry D., Downes C.P., Gray A., Humphries L.A., Rawlings D., Reynolds H., Vigorito E., and Turner M. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196 (2002) 753-763
78. Jou S.T., Carpino N., Takahashi Y., Piekorz R., Chao J.R., Carpino N., Wang D., and Ihle J.N. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22 (2002) 8580-8591
79. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., Sozzani S., Mantovani A., Altruda F., and Wymann M.P. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287 (2000) 1049-1053
80. Li Z., Jiang H., Xie W., Zhang Z., Smrcka A.V., and Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287 (2000) 1046-1049
81. Sasaki T., Irie-Sasaki J., Jones R.G., Oliveira-dos-Santos A.J., Stanford W.L., Bolon B., Wakeham A., Itie A., Bouchard D., Kozieradzki I., Joza N., Mak T.W., Ohashi P.S., Suzuki A., and Penninger J.M. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287 (2000) 1040-1046
82. + Foxp3+ regulatory T cells. J. Immunol. 177 (2006) 6598-6602
83. Rodriguez-Borlado L., Barber D.F., Hernandez C., Rodriguez-Marcos M.A., Sanchez A., Hirsch E., Wymann M., Martinez-A C., and Carrera A.C. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J. Immunol. 170 (2003) 4475-4482
84. Barber D.F., Bartolome A., Hernandez C., Flores J.M., Fernandez-Arias C., Rodriguez-Borlado L., Hirsch E., Wymann M., Balomenos D., and Carrera A.C. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 176 (2006) 589-593
85. Webb L.M., Vigorito E., Wymann M.P., Hirsch E., and Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 175 (2005) 2783-2787
86. Ji H., Rintelen F., Waltzinger C., Bertschy Meier D., Bilancio A., Pearce W., Hirsch E., Wymann M.P., Ruckle T., Camps M., Vanhaesebroeck B., Okkenhaug K., and Rommel C. Inactivation of PI3K{gamma} and PI3K{delta} distorts T cell development and causes multiple organ inflammation. Blood (2007)
87. Suzuki H., Terauchi Y., Fujiwara M., Aizawa S., Yazaki Y., Kadowaki T., and Koyasu S. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 283 (1999) 390-392
88. Saudemont A., Okkenhaug K., and Colucci F. p110delta is required for innate immunity to transplantable lymphomas. Biochem. Soc. Trans. 35 (2007) 183-185
89. Kim N., Saudemont A., Webb L., Camps M., Ruckle T., Hirsch E., Turner M., and Colucci F. The p110delta catalytic isoform of PI3K is a key player in NK cell development and cytokine secretion. Blood (2007)
90. Jones G.E., Prigmore E., Calvez R., Hogan C., Dunn G.A., Hirsch E., Wymann M.P., and Ridley A.J. Requirement for PI 3-kinase gamma in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res. 290 (2003) 120-131
91. Del Prete A., Vermi W., Dander E., Otero K., Barberis L., Luini W., Bernasconi S., Sironi M., Santoro A., Garlanda C., Facchetti F., Wymann M.P., Vecchi A., Hirsch E., Mantovani A., and Sozzani S. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J. 23 (2004) 3505-3515
92. Laffargue M., Calvez R., Finan P., Trifilieff A., Barbier M., Altruda F., Hirsch E., and Wymann M.P. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16 (2002) 441-451
93. Ali K., Bilancio A., Thomas M., Pearce W., Gilfillan A.M., Tkaczyk C., Kuehn N., Gray A., Giddings J., Peskett E., Fox R., Bruce I., Walker C., Sawyer C., Okkenhaug K., Finan P., and Vanhaesebroeck B. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431 (2004) 1007-1011
94. Kitaura J., Kinoshita T., Matsumoto M., Chung S., Kawakami Y., Leitges M., Wu D., Lowell C.A., and Kawakami T. IgE and IgE+Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 105 (2005) 3222-3229
95. Rivera J. NTAL/LAB and LAT: a balancing act in mast-cell activation and function. Trends Immunol. 26 (2005) 119-122
96. Gu H., Saito K., Klaman L.D., Shen J., Fleming T., Wang Y., Pratt J.C., Lin G., Lim B., Kinet J.P., and Neel B.G. Essential role for Gab2 in the allergic response. Nature 412 (2001) 186-190
97. Kraft S., and Kinet J.P. New developments in FcepsilonRI regulation, function and inhibition. Nat. Rev., Immunol. 7 (2007) 365-378
98. Wymann M.P., Bjorklof K., Calvez R., Finan P., Thomast M., Trifilieff A., Barbier M., Altruda F., Hirsch E., and Laffargue M. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. 31 (2003) 275-280
99. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
100. Steiner G. Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools. Clin. Rev. Allergy Immunol. 32 (2007) 23-36
101. Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., and Stuart J.M. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148 (1992) 2103-2108
102. Stuart J.M., Townes A.S., and Kang A.H. Collagen autoimmune arthritis. Annu. Rev. Immunol. 2 (1984) 199-218
103. Trentham D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 25 (1982) 911-916
104. Kerwar S.S., Englert M.E., McReynolds R.A., Landes M.J., Lloyd J.M., Oronsky A.L., and Wilson F.J. Type II collagen-induced arthritis. Studies with purified anticollagen immunoglobulin. Arthritis Rheum. 26 (1983) 1120-1131
105. Camps M., Ruckle T., Ji H., Ardissone V., Rintelen F., Shaw J., Ferrandi C., Chabert C., Gillieron C., Francon B., Martin T., Gretener D., Perrin D., Leroy D., Vitte P.A., Hirsch E., Wymann M.P., Cirillo R., Schwarz M.K., and Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11 (2005) 936-943
106. Singer G.G., Carrera A.C., Marshak-Rothstein A., Martinez C., and Abbas A.K. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. 6 (1994) 913-920
107. Cohen P.L., and Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9 (1991) 243-269
108. Barber D.F., Bartolome A., Hernandez C., Flores J.M., Redondo C., Fernandez-Arias C., Camps M., Ruckle T., Schwarz M.K., Rodriguez S., Martinez-A C., Balomenos D., Rommel C., and Carrera A.C. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11 (2005) 933-935
109. Di Cristofano A., Kotsi P., Peng Y.F., Cordon-Cardo C., Elkon K.B., and Pandolfi P.P. Impaired Fas response and autoimmunity in Pten+/- mice. Science 285 (1999) 2122-2125
110. Borlado L.R., Redondo C., Alvarez B., Jimenez C., Criado L.M., Flores J., Marcos M.A., Martinez-A C., Balomenos D., and Carrera A.C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14 (2000) 895-903
111. Chatham W.W., and Kimberly R.P. Treatment of lupus with corticosteroids. Lupus 10 (2001) 140-147
112. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
113. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
114. Biwa T., Sakai M., Matsumura T., Kobori S., Kaneko K., Miyazaki A., Hakamata H., Horiuchi S., and Shichiri M. Sites of action of protein kinase C and phosphatidylinositol 3-kinase are distinct in oxidized low density lipoprotein-induced macrophage proliferation. J. Biol. Chem. 275 (2000) 5810-5816
115. Biwa T., Sakai M., Shichiri M., and Horiuchi S. Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized low density lipoprotein-induced macrophage proliferation. J. Atheroscler. Thromb. 7 (2000) 14-20
116. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., and Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
117. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14 (1994) 133-140
118. Chang J.D., Sukhova G.K., Libby P., Schvartz E., Lichtenstein A.H., Field S.J., Kennedy C., Madhavarapu S., Luo J., Wu D., and Cantley L.C. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8077-8082
119. Lupia E., Goffi A., De Giuli P., Azzolino O., Bosco O., Patrucco E., Vivaldo M.C., Ricca M., Wymann M.P., Hirsch E., Montrucchio G., and Emanuelli G. Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am. J. Pathol. 165 (2004) 2003-2011
120. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
121. Schon M.P., and Boehncke W.H. Psoriasis. N. Engl. J. Med. 352 (2005) 1899-1912
122. Shapiro S.D. COPD unwound. N. Engl. J. Med. 352 (2005) 2016-2019
123. Ito K., Caramori G., and Adcock I.M. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharmacol. Exp. Ther. 321 (2007) 1-8
124. Hauser S.L., and Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52 (2006) 61-76
125. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev., Neurosci. 3 (2002) 291-301
126. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., Cantley L.C., and Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19 (2000) 2537-2548
127. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., Cantley L.C., and Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22 (2002) 2799-2809
128. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., Hirsch E., Suzuki A., Shioi T., Irie-Sasaki J., Sah R., Cheng H.Y., Rybin V.O., Lembo G., Fratta L., Oliveira-dos-Santos A.J., Benovic J.L., Kahn C.R., Izumo S., Steinberg S.F., Wymann M.P., Backx P.H., and Penninger J.M. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737-749
129. Luo J., McMullen J.R., Sobkiw C.L., Zhang L., Dorfman A.L., Sherwood M.C., Logsdon M.N., Horner J.W., DePinho R.A., Izumo S., and Cantley L.C. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 25 (2005) 9491-9502
130. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Fine R., Weis S., Hood J., Demaria A., Soll R., and Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19866-19871
131. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Hood J., and Soll R. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem. Soc. Trans. 35 (2007) 204-206
132. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
133. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev., Cancer 5 (2005) 921-929
134. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
135. Waite K.A., and Eng C. Protean PTEN: form and function. Am. J. Hum. Genet. 70 (2002) 829-844
136. Eng C. PTEN: one gene, many syndromes. Human Mutat. 22 (2003) 183-198
137. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., and Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16 (1997) 64-67
138. Marsh D.J., Dahia P.L., Zheng Z., Liaw D., Parsons R., Gorlin R.J., and Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16 (1997) 333-334
139. Smith J.M., Kirk E.P., Theodosopoulos G., Marshall G.M., Walker J., Rogers M., Field M., Brereton J.J., and Marsh D.J. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J. Med. Genet. 39 (2002) 937-940
140. Zhou X.P., Marsh D.J., Hampel H., Mulliken J.B., Gimm O., and Eng C. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum. Mol. Genet. 9 (2000) 765-768
141. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J. Med. Genet. 37 (2000) 828-830
142. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
143. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., and Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57 (1997) 4997-5000
144. Wu H., Goel V., and Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 22 (2003) 3113-3122
145. Khan S., Kumagai T., Vora J., Bose N., Sehgal I., Koeffler P.H., and Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 112 (2004) 407-410
146. Goel A., Arnold C.N., Niedzwiecki D., Carethers J.M., Dowell J.M., Wasserman L., Compton C., Mayer R.J., Bertagnolli M.M., and Boland C.R. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64 (2004) 3014-3021
147. Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., Kester M., Sandirasegarane L., and Robertson G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64 (2004) 7002-7010
148. Mirmohammadsadegh A., Marini A., Nambiar S., Hassan M., Tannapfel A., Ruzicka T., and Hengge U.R. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66 (2006) 6546-6552
149. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21 (1999) 99-102
150. Zhang A., Maner S., Betz R., Angstrom T., Stendahl U., Bergman F., Zetterberg A., and Wallin K.L. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int. J. Cancer 101 (2002) 427-433
151. Racz A., Brass N., Heckel D., Pahl S., Remberger K., and Meese E. Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur. J. Cancer 35 (1999) 641-646
152. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 (2006) 77-82
153. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
154. Miled N., Yan Y., Hon W.C., Perisic O., Zvelebil M., Inbar Y., Schneidman-Duhovny D., Wolfson H.J., Backer J.M., and Williams R.L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317 (2007) 239-242
155. Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., and Omata M. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65 (2005) 4562-4567
156. Kang S., Bader A.G., and Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 802-807
157. Samuels Y., Diaz L.A.J., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
158. Cheadle J.P., Reeve M.P., Sampson J.R., and Kwiatkowski D.J. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107 (2000) 97-114
159. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., and Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13 (2003) 2004-2008
160. Boudeau J., Sapkota G., and Alessi D.R. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett. 546 (2003) 159-165
161. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev., Cancer 4 (2004) 335-348
162. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
163. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., and Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
164. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., Natt F., Hall J., Lane H.A., and Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
165. Dann S.G., Selvaraj A., and Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13 (2007) 252-259
166. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., and Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24 (2004) 9508-9516
167. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
168. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., and Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
169. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
170. Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci. STKE 2006 (2006) re7
171. Foukas L.C., Claret M., Pearce W., Okkenhaug K., Meek S., Peskett E., Sancho S., Smith A.J., Withers D.J., and Vanhaesebroeck B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006) 366-370
172. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B.r., Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001) 1728-1731
173. George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J., Stoffel M., O'Rahilly S., and Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304 (2004) 1325-1328
174. Bandyopadhyay G.K., Yu J.G., Ofrecio J., and Olefsky J.M. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54 (2005) 2351-2359
175. Tremblay F., Krebs M., Dombrowski L., Brehm A., Bernroider E., Roth E., Nowotny P., Waldhausl W., Marette A., and Roden M. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 54 (2005) 2674-2684
176. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., and Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16 (1996) 1722-1733
177. Arcaro A., and Wymann M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296 (1993) 297-301
178. Yano H., Nakanishi S., Kimura K., Hanai N., Saitoh Y., Fukui Y., Nonomura Y., and Matsuda Y. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 268 (1993) 25846-25856
179. Wymann M., and Arcaro A. Platelet-derived growth factor-induced phosphatidylinositol 3-kinase activation mediates actin rearrangements in fibroblasts. Biochem. J. 3 (1994) 517-520 (298 Pt.)
180. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
181. Li B., Liu Y., Uno T., and Gray N. Creating chemical diversity to target protein kinases. Comb. Chem. High Throughput Screen. 7 (2004) 453-472
182. Parang K., and Sun G. Design strategies for protein kinase inhibitors. Curr. Opin. Drug Discov. Dev. 7 (2004) 617-629
183. Walker E.H., Perisic O., Ried C., Stephens L., and Williams R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (1999) 313-320
184. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
185. Stoyanova S., Bulgarelli-Leva G., Kirsch C., Hanck T., Klinger R., Wetzker R., and Wymann M.P. Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin. Biochem. J. 324 (1997) 489-495
186. Brian P.W., Curtis P.J., Hemming H.G., and Norris G.L.F. Wortmannin, an antibiotic produced by Penicillium wortmanni. Trans. Br. Mycol. Soc. 40 (1957) 365-368
187. MacMillan J., Vanstone A.E., and Yeboah S.K. The structure of wortmannin, a steroidal fungal metabolite. J. Chem. Soc., Chem. Commun. 388 (1968) 613-614
188. MacMillan J., Vanstone A.E., and Yeboah S.K. Fungal products: Part III. Structure of wortmannin and some hydrolysis products. J. Chem. Soc. 1 (1972) 2898-2903
189. Simpson T.J., Lunnon M.W., and MacMillan J. Fungal products: Part 21. Biosynthesis of the fungal metabolite, wortmannin, from (1,2-13C2)-acetate. J. Chem. Soc., Perkin Trans. 1 (1979) 931-934
190. Petcher T.J., Weber H., and Kis Z. Crystal structure and absolute configuration of wortmannin and of wortmannin p-bromobenzoate. J. Chem. Soc., Chem. Commun. (1972) 1061-1062
191. Baggiolini M., Dewald B., Schnyder J., Ruch W., Cooper P.H., and Payne T.G. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp. Cell Res. 169 (1987) 408-418
192. Thelen M., Wymann M.P., and Langen H. Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4960-4964
193. Wipf P., and Halter R.J. Chemistry and biology of wortmannin. Org. Biomol. Chem. 3 (2005) 2053-2061
194. Bonser R.W., Thompson N.T., Randall R.W., Tateson J.E., Spacey G.D., Hodson H.F., and Garland L.G. Demethoxyviridin and wortmannin block phospholipase C and D activation in the human neutrophil. Br. J. Pharmacol. 103 (1991) 1237-1241
195. Woscholski R., Kodaki T., McKinnon M., Waterfield M.D., and Parker P.J. A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase. FEBS Lett. 342 (1994) 109-114
196. Aldridge D.C., Turner W.B., Geddes A.J., and Sheldrick B. Demethoxyviridin and demethoxyviridiol: new fungal metabolites. J. Chem. Soc., Perkin Trans. 1 (1975) 943-945
197. Norman B.H., Shih C., Toth J.E., Ray J.E., Dodge J.A., Johnson D.W., Rutherford P.G., Schultz R.M., Worzalla J.F., and Vlahos C.J. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem. 39 (1996) 1106-1111
198. Hartley K.O., Gell D., Smith G.C., Zhang H., Divecha N., Connelly M.A., Admon A., Lees-Miller S.P., Anderson C.W., and Jackson S.P. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 82 (1995) 849-856
199. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence J.C.J., and Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15 (1996) 5256-5267
200. Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., and Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58 (1998) 4375-4382
201. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., and Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
202. Holleran J.L., Fourcade J., Egorin M.J., Eiseman J.L., Parise R.A., Musser S.M., White K.D., Covey J.M., Forrest G.L., and Pan S.S. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metab. Dispos. 32 (2004) 490-496
203. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., Minion D.J., Halter R.J., Wipf P., Abraham R., Kirkpatrick L., and Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3 (2004) 763-772
204. Giner J.L., Kehbein K.A., Cook J.A., Smith M.C., Vlahos C.J., and Badwey J.A. Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase. Bioorg. Med. Chem. Lett. 16 (2006) 2518-2521
205. Yuan H., Luo J., Field S., Weissleder R., Cantley L., and Josephson L. Synthesis and activity of C11-modified wortmannin probes for PI3 kinase. Bioconjug. Chem. 16 (2005) 669-675
206. Yee M.C., Fas S.C., Stohlmeyer M.M., Wandless T.J., and Cimprich K.A. A cell-permeable, activity-based probe for protein and lipid kinases. J. Biol. Chem. 280 (2005) 29053-29059
207. Liu Y., Shreder K.R., Gai W., Corral S., Ferris D.K., and Rosenblum J.S. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12 (2005) 99-107
208. Liu Y., Jiang N., Wu J., Dai W., and Rosenblum J.S. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J. Biol. Chem. 282 (2007) 2505-2511
209. Marion F., Williams D.E., Patrick B.O., Hollander I., Mallon R., Kim S.C., Roll D.M., Feldberg L., Van Soest R., and Andersen R.J. Liphagal, a selective inhibitor of PI3 kinase alpha isolated from the sponge akacoralliphaga: structure elucidation and biomimetic synthesis. Org. Lett. 8 (2006) 321-324
210. Foukas L.C., Daniele N., Ktori C., Anderson K.E., Jensen J., and Shepherd P.R. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J. Biol. Chem. 277 (2002) 37124-37130
211. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev., Drug Discov. 5 (2006) 493-506
212. Siemann E.H., and Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic. 43 (1992) 49-52
213. Frojdo S., Cozzone D., Vidal H., and Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 406 (2007) 511-518
214. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
215. Knight Z.A., Chiang G.G., Alaimo P.J., Kenski D.M., Ho C.B., Coan K., Abraham R.T., and Shokat K.M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12 (2004) 4749-4759
216. Gharbi S.I., Zvelebil M.J., Shuttleworth S.J., Hancox T., Saghir N., Timms J.F., and Waterfield M.D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404 (2007) 15-21
217. Sadhu C., Masinovsky B., Dick K., Sowell C.G., and Staunton D.E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170 (2003) 2647-2654
218. Sadhu C., Dick K., Tino W.T., and Staunton D.E. Selective role of PI3K delta in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 308 (2003) 764-769
219. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., Vanhaesebroeck B., Muller O., Pesce F., Ifrah N., Hunault-Berger M., Berthou C., Villemagne B., Jourdan E., Audhuy B., Solary E., Witz B., Harousseau J.L., Himberlin C., Lamy T., Lioure B., Cahn J.Y., Dreyfus F., Mayeux P., Lacombe C., and Bouscary D. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106 (2005) 1063-1066
220. Billottet C., Grandage V.L., Gale R.E., Quattropani A., Rommel C., Vanhaesebroeck B., and Khwaja A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25 (2006) 6648-6659
221. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., Balla T., Weiss W.A., Williams R.L., and Shokat K.M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
222. Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., Kenche V., Anderson K.E., Dopheide S.M., Yuan Y., Sturgeon S.A., Prabaharan H., Thompson P.E., Smith G.D., Shepherd P.R., Daniele N., Kulkarni S., Abbott B., Saylik D., Jones C., Lu L., Giuliano S., Hughan S.C., Angus J.A., Robertson A.D., and Salem H.H. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 11 (2005) 507-514
223. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell Int. 9 (2006) 341-349
224. Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., Bjerke L.M., Kelland L., Valenti M., Patterson L., Gowan S., de Haven Brandon A., Hayakawa M., Kaizawa H., Koizumi T., Ohishi T., Patel S., Saghir N., Parker P., Waterfield M., and Workman P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67 (2007) 5840-5850
225. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., Raynaud F.I., Workman P., Waterfield M.D., and Parker P. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2438-2442
226. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Okada M., Ohta M., Tsukamoto S., Parker P., Workman P., and Waterfield M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 14 (2006) 6847-6858
227. Condliffe A.M., Davidson K., Anderson K.E., Ellson C.D., Crabbe T., Okkenhaug K., Vanhaesebroeck B., Turner M., Webb L., Wymann M.P., Hirsch E., Ruckle T., Camps M., Rommel C., Jackson S.P., Chilvers E.R., Stephens L.R., and Hawkins P.T. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (2005) 1432-1440
228. Hayakawa M., Kaizawa H., Kawaguchi K., Ishikawa N., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., Raynaud F.I., Waterfield M.D., Parker P., and Workman P. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 15 (2007) 403-412
229. Pomel V., Klicic J., Covini D., Church D.D., Shaw J.P., Roulin K., Burgat-Charvillon F., Valognes D., Camps M., Chabert C., Gillieron C., Francon B., Perrin D., Leroy D., Gretener D., Nichols A., Vitte P.A., Carboni S., Rommel C., Schwarz M.K., and Ruckle T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49 (2006) 3857-3871
230. Yaguchi S., Fukui Y., Koshimizu I., Yoshimi H., Matsuno T., Gouda H., Hirono S., Yamazaki K., and Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 98 (2006) 545-556
231. Palanki M.S., Dneprovskaia E., Doukas J., Fine R.M., Hood J., Kang X., Lohse D., Martin M., Noronha G., Soll R.M., Wrasidlo W., Yee S., and Zhu H. Discovery of 3,3′-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J. Med. Chem. 50 (2007) 4279-4294
232. Yang J., Shamji A., Matchacheep S., and Schreiber S.L. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem. Biol. 14 (2007) 371-377
233. Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., and Waterfield M.D. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 24 (1994) 472-477
234. Hu P., Mondino A., Skolnik E.Y., and Schlessinger J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13 (1993) 7677-7688
235. Stoyanov B., Volinia S., Hanck T., Rubio I., Loubtchenkov M., Malek D., Stoyanova S., Vanhaesebroeck B., Dhand R., Nurnberg B., et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269 (1995) 690-693
236. Seki N., Nimura Y., Ohira M., Saito T., Ichimiya S., Nomura N., and Nakagawara A. Identification and chromosome assignment of a human gene encoding a novel phosphatidylinositol-3 kinase. DNA Res. 4 (1997) 355-358
237. Vanhaesebroeck B., Welham M.J., Kotani K., Stein R., Warne P.H., Zvelebil M.J., Higashi K., Volinia S., Downward J., and Waterfield M.D. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4330-4335
238. Volinia S., Patracchini P., Otsu M., Hiles I., Gout I., Calzolari E., Bernardi F., Rooke L., and Waterfield M.D. Chromosomal localization of human p85 alpha, a subunit of phosphatidylinositol 3-kinase, and its homologue p85 beta. Oncogene 7 (1992) 789-793
239. Janssen J.W., Schleithoff L., Bartram C.R., and Schulz A.S. An oncogenic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 16 (1998) 1767-1772
240. Dey B.R., Furlanetto R.W., and Nissley S.P. Cloning of human p55 gamma, a regulatory subunit of phosphatidylinositol 3-kinase, by a yeast two-hybrid library screen with the insulin-like growth factor-I receptor. Gene 209 (1998) 175-183
241. Stephens L.R., Eguinoa A., Erdjument-Bromage H., Lui M., Cooke F., Coadwell J., Smrcka A.S., Thelen M., Cadwallader K., Tempst P., and Hawkins P.T. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89 (1997) 105-114
242. Suire S., Coadwell J., Ferguson G.J., Davidson K., Hawkins P., and Stephens L. p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr. Biol. 15 (2005) 566-570
243. Domin J., Pages F., Volinia S., Rittenhouse S.E., Zvelebil M.J., Stein R.C., and Waterfield M.D. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326 (1997) 139-147
244. Brown R.A., Ho L.K., Weber-Hall S.J., Shipley J.M., and Fry M.J. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem. Biophys. Res. Commun. 233 (1997) 537-544
245. Rozycka M., Lu Y.J., Brown R.A., Lau M.R., Shipley J.M., and Fry M.J. cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 54 (1998) 569-574
246. Volinia S., Dhand R., Vanhaesebroeck B., MacDougall L.K., Stein R., Zvelebil M.J., Domin J., Panaretou C., and Waterfield M.D. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 14 (1995) 3339-3348
247. Panaretou C., Domin J., Cockcroft S., and Waterfield M.D. Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150.Ptdins 3-kinase complex. J. Biol. Chem. 272 (1997) 2477-2485
248. Wong K., and Cantley L.C. Cloning and characterization of a human phosphatidylinositol 4-kinase. J. Biol. Chem. 269 (1994) 28878-28884
249. Meyers R., and Cantley L.C. Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. J. Biol. Chem. 272 (1997) 4384-4390
250. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., and Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
251. Sipley J.D., Menninger J.C., Hartley K.O., Ward D.C., Jackson S.P., and Anderson C.W. Gene for the catalytic subunit of the human DNA-activated protein kinase maps to the site of the XRCC7 gene on chromosome 8. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7515-7519
252. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G., Taylor A.M., Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., and Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1753
253. Cimprich K.A., Shin T.B., Keith C.T., and Schreiber S.L. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2850-2855
254. Diaz-Meco M.T., Municio M.M., Sanchez P., Lozano J., and Moscat J. Lambda-interacting protein, a novel protein that specifically interacts with the zinc finger domain of the atypical protein kinase C isotype lambda/iota and stimulates its kinase activity in vitro and in vivo. Mol. Cell. Biol. 16 (1996) 105-114
255. Yamashita A., Ohnishi T., Kashima I., Taya Y., and Ohno S. Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes Dev. 15 (2001) 2215-2228
256. McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., and Cole M.D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94 (1998) 363-374
257. Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., and Nakatani Y. The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol. Cell 2 (1998) 869-875
258. Lau A., Swinbank K.M., Ahmed P.S., Taylor D.L., Jackson S.P., Smith G.C., and O'Connor M.J. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat. Cell Biol. 7 (2005) 493-500
259. Powis G., Bonjouklian R., Berggren M.M., Gallegos A., Abraham R., Ashendel C., Zalkow L., Matter W.F., Dodge J., Grindey G., et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 54 (1994) 2419-2423
260. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. Allied Res. India 67 (1998) 481-507
261. Smith G.C., and Jackson S.P. The DNA-dependent protein kinase. Genes Dev. 13 (1999) 916-934
262. Hayakawa M., Kawaguchi K., Kaizawa H., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., Raynaud F.I., Parker P., Workman P., and Waterfield M.D. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 15 (2007) 5837-5844
263. Kendall J.D., Rewcastle G.W., Frederick R., Mawson C., Denny W.A., Marshall E.S., Baguley B.C., Chaussade C., Jackson S.P., and Shepherd P.R. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. Bioorg. Med. Chem. 15 (2007) 7677-7687
264. Minogue S., Anderson J.S., Waugh M.G., dos Santos M., Corless S., Cramer R., and Hsuan J.J. Cloning of a human type II phosphatidylinositol 4-kinase reveals a novel lipid kinase family. J. Biol. Chem. 276 (2001) 16635-16640
265. Minogue S., Anderson J.S., Waugh M.G., dos Santos M., Corless S., Cramer R., and Hsuan J.J. Cloning of a human type II phosphatidylinositol 4-kinase reveals a novel lipid kinase family. J. Biol. Chem. 276 (2001) 16635-16640
266. Balla A., Tuymetova G., Barshishat M., Geiszt M., and Balla T. Characterization of type II phosphatidylinositol 4-kinase isoforms reveals association of the enzymes with endosomal vesicular compartments. J. Biol. Chem. 277 (2002) 20041-20050